Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Venatorx Pharmaceuticals Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active case is assigned to a distinct examiner and 1 distinct art unit, showing a concentrated prosecution effort. This focus suggests that the company's current intellectual property strategy is centered on a specific pharmaceutical innovation. Such a targeted approach allows for deep specialization in a particular technical domain.
The busiest examiner for the company is YOO, SUN JAE, who is responsible for 1 busiest examiner pending office action. Since the total number of pending office actions is 1, this examiner is the only official currently reviewing the company's active applications. With only 1 distinct art unit involved, the company's immediate success at the patent office depends on the specific examination standards and history of that administrative group. This singular focus ensures that the outcome of this case will define the company's current patent standing. YOO, SUN JAE will be the primary official for this matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| No statute on record | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOO, SUN JAE | 1 | 71.2% | +0.3% |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18819935 | BETA-LACTAMASE INHIBITORS | YOO, SUN JAE | 1621 | Other | Non-Final OA | — | Pending | Aug 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVenatorx Pharmaceuticals Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sun Jae Yoo has the most, with 1 of Venatorx Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
